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Bochenek et al. Systemic Measures for Drug Shortages
Drug shortages have been identiﬁed as a public health problem in an increasing number
of countries. This can negatively impact on the quality and efﬁciency of patient care, as
well as contribute to increases in the cost of treatment and the workload of health care
providers. Shortages also raise ethical and political issues. The scientiﬁc evidence on drug
shortages is still scarce, but many lessons can be drawn from cross-country analyses.
The objective of this study was to characterize, compare, and evaluate the current
systemic measures and legislative and organizational frameworks aimed at preventing
or mitigating drug shortages within health care systems across a range of European
and Western Asian countries. The study design was retrospective, cross-sectional,
descriptive, and observational. Information was gathered through a survey distributed
among senior personnel from ministries of health, state medicines agencies, local health
authorities, other health or pharmaceutical pricing and reimbursement authorities, health
insurance companies and academic institutions, with knowledge of the pharmaceutical
markets in the 28 countries studied. Our study found that formal deﬁnitions of drug
shortages currently exist in only a few countries. The characteristics of drug shortages,
including their assortment, duration, frequency, and dynamics, were found to be variable
and sometimes difﬁcult to assess. Numerous information hubs were identiﬁed. Providing
public access to information on drug shortages to the maximum possible extent is
a prerequisite for performing more advanced studies on the problem and identifying
solutions. Imposing public service obligations, providing the formal possibility to prescribe
unlicensedmedicines, and temporary bans on parallel exports are widespreadmeasures.
A positive ﬁnding of our study was the identiﬁcation of numerous bottom-up initiatives
and organizational frameworks aimed at preventing or mitigating drug shortages. The
experiences and lessons drawn from these initiatives should be carefully evaluated,
monitored, and presented to a wider international audience for careful appraisal. To
be able to ﬁnd solutions to the problem of drug shortages, there is an urgent need to
develop a set of agreed deﬁnitions for drug shortages, as well as methodologies for their
evaluation and monitoring. This is being progressed.
Keywords: drug shortage, pharmaceutical policy, health care system, legislation, organizational framework,
Europe, European Union, Western Asia
INTRODUCTION
We are accustomed to thinking that commodities produced
anywhere across the globe will be available to consumers within
a relatively short period of time, if not immediately. Typically,
access to sufficient financial resources has been the only obstacle
Abbreviations: AEMPS, (in Spanish) Spanish Agency for Medicines and Health
Products; AIFA, (in Italian) Italian Medicines Agency; ANSM, (in French) French
Agency for Medicines Safety; CISMED, (in Spanish) Center for Information
on Medicines Supply; EMA, European Medicines Agency; EOF, (in Greek)
National Organization for Medicines; EU, European Union; FAMHP, Federal
Agency of Medicines and Health Products (Belgium); FONES, Federal Office of
National Economic Supply (Switzerland); GMP, Good Manufacturing Practice;
MA, marketing authorization; MAH, Marketing authorization holder; MoH,
Ministry/Minister of Health; NGO, Non-governmental organization; NIHDI,
National Institute of Health and Disability Insurance (Belgium); NoMA,
Norwegian Medicines Agency; PSO, Public service obligation; SAMLV, State
Medicines Agency in Latvia; SMCA, State Medicines Control Agency (Lithuania);
SOP, Standard operating procedures; TI˙TCK, Turkish Medicines and Medical
Devices Agency.
in acquiring these products. Despite this, and surprisingly, in
the second decade of the twenty-first century, shortages of
pharmaceuticals have increasingly become an issue in many
countries for a number of reasons. Drug shortages has been
the focus of academic and practitioner research, initially in the
USA and Canada, but subsequently in a number of European
countries and other continents (Morrison, 2011; Ventola, 2011;
Birgli, 2013; McBride et al., 2013; Costelloe et al., 2014; Goldsack
et al., 2014; Bogaert et al., 2015; Butterfield et al., 2015; De
Weerdt et al., 2015b, 2017b; Pauwels et al., 2015; Alsheikh et al.,
2016; Awad et al., 2016; Yang et al., 2016; Heiskanen et al.,
2017; Mazer-Amirshahi et al., 2017; Walker et al., 2017). Some
medicines are simply not available on the market in certain
countries, even if there is sufficient money to pay for them.
The scientific evidence underpinning drug shortages, including
the extent and rationale, is still scarce. However, the amount
of evidence is gradually increasing and the problem is now a
permanent feature within the public and scientific discourse.
This problem needs to be addressed urgently, especially for
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critical medicines, in order to avoid any negative impact on
patients.
One of the seminal cross-country reports on drug shortages in
Europe, including an in-depth analysis of the situation in France,
Greece, Poland, Spain, and the United Kingdom, proposed
a classification of reasons for shortages into unpredictable
and predictable issues (Birgli, 2013). The first category of
reasons embraces natural disasters, manufacturing problems, raw
material shortages, non-compliance with regulatory standards,
packaging shortages, unexpected demand, epidemics, parallel
distribution, competitive issues, foreign exchange effect, and
sovereignty issues (e.g., a financial crisis). The predictable reasons
include: product discontinuation, industry consolidation, limited
manufacturing capacity, just-in-time inventories, rationing and
quotas, deliberate shortages to manipulate price, market shifts,
the launch of a new competitor or formulation, and patent expiry
(Birgli, 2013).
The characteristics of drug shortages, such as the assortment
or range of non-available products, are different in each country
but there are some common themes. In the USA, the majority
of shortages were reported to occur among sterile injectable
medications (McLaughlin and Skoglund, 2015). In addition,
the number of generic medicines experiencing shortages in
the USA has risen appreciably in recent years from 154 in
2007 to 456 in 2012 (United States Government Accountability
Office Report, 2014). In several European countries, for example
Belgium, the Netherlands, the United Kingdom (England), Italy,
Germany, Spain, and France, injectable forms dominated reports
on shortages in two categories: oncology medicines (79%) and
medicines defined as essential by the WHO (52%; Pauwels et al.,
2014; World Health Organization, 2017). Drug shortages have an
indisputable impact on public health, especially when they cause
a delay in starting treatment or difficulty in its continuation,
lowering or omitting doses, increasing costs of treatment,
selection of patients, or putting an increased administrative
burden on health care staff (Ventola, 2011; McLaughlin et al.,
2013; Bocquet et al., 2017; De Weerdt et al., 2017b).
According to a survey performed among anesthesiologists
in the USA, 90% experienced a problem with shortages of
anesthetics (with at least one drug) at the time of the survey,
while this increased to 98% in the last year (American Society of
Anesthesiologists, 2017). Moreover, 92% linked the shortage with
the necessity to use alternative drugs, 6% had to postpone and 4%
had to cancel procedures (American Society of Anesthesiologists,
2017). From the hospital pharmacists’ perspective, according to
a survey on shortages of injectable medicines, the impact of
shortages in the USA was significant (Goldsack et al., 2014). As
many as 99% of pharmacists reported experiencing at least one
drug shortage during the previous 12 months, 64% reported that
their facility had completely run out of at least one injectable
oncology drug during that period of time and 25% reported
that one or more safety events had occurred at their facility
as a result of drug shortages (Goldsack et al., 2014). Shortages
were forcing hospitals to apply various management strategies–
83% of respondents reported that providers may have changed
the treatment of their patients as a result of drug shortages,
43% reported treatment delays and 38%—the prioritization
of patients for treatment based on clinical factors. Moreover,
shortages of injectable oncology drugs had a direct impact
on treatment costs: for example, 74% of respondents reported
that their facility had received an offer to purchase drugs in
short supply at a higher price, and 65% reported that overall
treatment costs had increased due to drug shortages. The major
cost drivers were primarily: increased labor spending, expansion
of inventory levels, purchasing of more expensive (branded or
generic) substitute drugs, and purchasing of a drug in short
supply from an alternate supplier at a higher price (Goldsack
et al., 2014).
Similar to the USA, drug shortages have also been reported
in European countries to have a serious impact on health care
systems and public health [European Association of Hospital
Pharmacists (EAHP) secretariat, 2014; Pauwels et al., 2015].
A large pan-European survey on medicines supply shortages
in the hospital sector, their prevalence, nature, and impact
on patient care, revealed that 75% of responders (hospital
pharmacists) agree or strongly agree that shortages had a
negative impact on patient care in their hospitals [European
Association of Hospital Pharmacists (EAHP) secretariat, 2014].
The majority of hospital pharmacists, responding to questions in
another pan-European survey, indicated increased hospital costs,
pharmacy or personnel costs, and the use of more expensive
alternatives as frequently or always occurring consequences of
drug shortages (Pauwels et al., 2015). As far as the level of
personnel stress was concerned, 37% of respondents indicated
that drug shortages influenced it very severely. The total time
spent on the management of drug shortages was estimated
to be 13 h per week (Pauwels et al., 2015). Belgian hospital
pharmacists spent a median of 109min a week on drug supply
problems, carrying out 59% of the total time spent on these
problems in their hospitals and being supported by pharmacy
technicians (27% of the total time), and logistic or administrative
personnel (De Weerdt et al., 2017a). The Flemish community
pharmacists spent approximately half an hour per week on drug
supply problems, mainly checking missing products from orders,
contacting wholesalers or manufacturers regarding potential
drug shortages and communicating to patients (DeWeerdt et al.,
2017c).
Drug shortages can also be considered as ethical and political
issues. They threaten the capacity for clinicians and governments
to fulfill their moral obligations to patients and society associated
with providing benefit, minimizing harm and promoting equity,
especially in Europe. Moreover, they stem from societal values,
especially from the choices that societies have made about what
they want most from pharmaceutical industries, regulators, and
health services (Lipworth and Kerridge, 2013). In the USA, the
challenge was explicitly expressed as “No more denying. You are
in denial too if you believe that this country’s pharmaceutical
industry (. . . ) can reliably supply medications for patients.”
(Wenzel, 2015). There is an ethical imperative to prevent drug
shortages. However, these shortages stem partly from choices that
societies make about how they want to organize their markets,
health care services and regulatory environment and, for that
reason, any proposed solution will likely threaten the various
stakeholder groups’ values and require moral trade-offs, difficult
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choices within health care systems, and reordering priorities
(Lipworth and Kerridge, 2013; Schweitzer, 2013).
The focus of our previous study was analyzing, characterizing
and assessing drug shortages in Belgium and France, while also
adopting a wider perspective from the European Union (EU).
We identified and addressed four major themes: (a) defining
drug shortages, (b) their dynamics and perception, (c) their
determinants, and (d) the role of the European and national
institutions in coping with the problem (Bogaert et al., 2015).
We found that there are three major groups of determinants to
this problem: manufacturing problems, distribution and supply
problems, and problems related to economic aspects. The EU
Member States are striving to resolve this problem very much on
their own, although there is an initiative run by the European
Medicines Agency (EMA) whereby a Shortages Catalogue is
being maintained by the EMA (European Medicines Agency,
2017). A far more focused and dedicated collaboration may
well prove instrumental in coping more effectively with drug
shortages.
Learning from other countries’ experiences should not be
underestimated or underutilized in shaping local or national
pharmaceutical policies (Godman et al., 2010, 2014; Voncˇina
et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario
et al., 2017). There could be lessons to be drawn from cross-
country comparisons, even if a given country’s characteristics
do not perfectly correspond in terms of geographical location,
size, demography, economy, or type of health care system.
Consequently, the objective of the current study was to
characterize, compare, and evaluate the current systemic
measures, legislation, and legislative frameworks aimed at
preventing or mitigating drug shortages existing within health
care systems across a wide range of European andWestern Asian
countries.
MATERIALS AND METHODS
The design of this study was retrospective, cross-sectional,
descriptive, and observational. To achieve the objective of this
study, a survey form was prepared. It contained questions
pertaining to: (1) general characteristics of drug shortages; (2)
alertness to drug shortages and a description of the information
systems to capture shortages; (3) public service obligations; and
(4) regulations associated with the problem of drug shortages.
Full information on content of a survey form, including all
detailed questions, can be found as Supplementary Material. The
survey formwas pilot-tested on five international pharmaceutical
market professionals before being issued. Information was
gathered through an interactive, iterative process. Written
responses to the survey questions were given by the co-authors,
who are typically senior health authority, health insurance
company personnel or their advisers, and were knowledgeable
about the current situation in the national pharmaceutical
markets of all the included countries. They represented personnel
from ministries of health, state medicines agencies, local
health authorities, other health or pharmaceutical pricing and
reimbursement authorities, health insurance companies and
academic institutions. The responses to survey questions were
verified for accuracy and appropriate understanding of the
country-specific arrangements by checking documents, legal acts,
and regulations pertinent to the studied problems. They were re-
checked and re-confirmed with the co-authors to enhance the
robustness of the findings and potential ways forward.
To further enhance the robustness of the study results,
the published sources, including the scientific literature, legal
acts and information gathered and disclosed within the public
domain by organizations involved in pharmaceutical markets of
the studied countries, were used as well. The methodological
strategy used in this study was case-oriented, seeking to better
understand the dynamics of the global problem of drug shortages,
based on a number of cases selected from countries of Europe
and Western Asia, characterized by different epidemiologies,
geographies, GDPs per capita, levels of spending on health care,
and approaches to the pricing of medicines (Cacace et al., 2013).
The potential respondents representing all 28 member countries
of the EU and 4 of the European Free Trade Association (EFTA),
as well as 10 non-EU/EFTA countries were invited to participate
in this study. Respondents from 14 countries either declined to
participate or returned incomplete surveys which could not be
improved or corrected. The response rate was 67%. Therefore,
the overall number of the included countries was 28 and this
group consisted of 20 EU/EFTA countries and 8 non-EU/EFTA
countries. This cross-country comparative study reflects the
situation as in spring 2017.
The policy document analysis approach was applied in this
study, and no interviews, requiring recruitment and obtaining
informed consent from humans were conducted. Information
that can be disclosed to the public and/or is accessible in
the public domain was sought in this study. Consequently,
ethics approval was not required and the study has no ethical
implications associated with its design and conduct.
RESULTS
Definitions, Occurrence, and Dynamics of
Drug Shortages
Formal and legally binding definitions of drug shortages
currently do not exist in the majority of the studied countries,
with the exception of Belgium, France, Italy, and Spain, where
the most comprehensive descriptions were coined. The situation
of the unavailability ofmedicines on the Belgianmarket is defined
as follows: “A drug is unavailable when enterprises that are
responsible for the marketing of the drug are unable to deliver
that drug for an uninterrupted period of four consecutive days to
the community pharmacies, hospital pharmacies or wholesalers
in Belgium1.” Moreover, a second definition was formulated
through regulations for reporting unavailability: “Holders of
the market authorization should notify the Federal Agency of
Medicines and Health Products (FAMHP) when a drug will
be unavailable for a time period longer than 14 days. The
1Belgian Parliament. Belgian law on compulsory insurances for medical care
coordinated on 14th July 1994 –art.72bis (Flemish: Wet Betreffende de Verplichte
Verzekering Voor Geneeskundige Verzorging En Uitkeringen Gecoördineerd Op
14 Juli, 1994), Belgium.
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notification should be made within 7 days after the start of
the unavailability” (De Weerdt et al., 2015a). A drug shortage
is defined by law in France as an inability for a community
pharmacy or a hospital pharmacy to deliver a drug within 72
h2 Additionally, drug shortages in France have been classified
formally into two separate contexts of either stock or supply
problems. A stock-related shortage is defined as the lack of
possibility to manufacture a medicine, whereas a supply-related
shortage is defined as a problem in the distribution chain that
makes the supply of a medicine impossible, even if enough of the
medicine has been manufactured2. A formal, legal description of
drug shortages also exists in Italy. The Italian Medicines Agency
(AIFA) defines medicines in short supply as: “Medicines which
are not available or not to be found on the whole Italian market,
because the marketing authorization holder (MAH) is unable
to guarantee the correct and regular supply to meet patients’
needs3”.
Although in Spain there was no single standard definition
established for the whole country (which was reported as a rather
serious problem in monitoring shortages), several definitions
were coined by different entities. The Spanish Agency for
Medicines and Health Products (Spanish acronym: AEMPS),
being part of the Spanish Ministry of Health Care, defined the
“supply problem” as a situation in which the number of available
units of a drug in the pharmaceutical trade channel is below the
level of national or local consumption needs, being often due to
problems in the manufacturing or distribution of a drug4. The
Regional Government ofMadrid defined the “supply problem” as
a continued andwidespread shortage of a drug in pharmacies that
may be due to problems in manufacturing, procurement of raw
materials or distribution5. The Government of Valencia approved
a regulation in 2008 where “insufficient supply” was delineated
very precisely. It allows the Department of Health to proclaim the
state of “insufficient supply,” in order to avoid serious problems
with supply of medicines or their shortages. Proclamation is
based on signals gathered from the pharmaceutical market,
observations of processing of drug supply orders and frequency
of substitution of prescriptions for a particular drug. All this
information is reported through a pharmaceutical information
system named Gaia6.
Two descriptions of situations associated with drug shortages
currently exist in Greece (actual shortages and temporary
interruptions in supply), although a coherent, official definition,
considering the duration of a shortage, does not currently exist in
2French Parliament. The Public health code. Article, R. 5124-49-1. Available
online at: https://www.legifrance.gouv.fr/affichCodeArticle.do?cidTexte=
LEGITEXT000006072665&idArticle=LEGIARTI000026428604&dateTexte=&
categorieLien=cid
3Italian Medicines Agency. Available online at: http://www.agenziafarmaco.gov.it/
it/content/carenze-dei-medicinali
4Spanish Agency for Medicines and Health Products. Supply Shortages
of Medicinal Products. Available online at: https://www.aemps.gob.es/
medicamentosUsoHumano/problemasSuministro/home.htm
5Regional Government of Madrid. Medicamentos con problemas de suministro.
Available online at: http://www.madrid.org/cs/Satellite?cid=1142686373465&
language=es&pagename=PortalSalud%2FPage%2FPTSA_pintarContenidoFinal&
vest=1142645418945
6Government of Valencia. Law 1/2008, of April 17, on Guarantees for the Supply
of Medicines. Article 3.
the country. The situation of an actual drug shortage pertains to
the lack of capability to fulfill the demand and the non-availability
of a drug in the whole health care system, without the possibility
to obtain that medicine from any source. Interruptions in supply
refer to situations when drugs are not commercially available,
mainly for commercial reasons, for a limited time duration.
In the rest of the studied countries, only indirect formal
descriptions of situations pertaining to the problem of drug
shortages were found, but they cannot be considered as
straightforward definitions. They are associated with the
revocation of marketing authorization (MA) in cases of not
placing a product on the market, not responding to requests
of supply from hospitals, as well as situations of suspending
distribution or disrupting supplies of medicines.
Interestingly, in Hungary, “drug shortage” as a term is
reported to be widely used in the legislation, including the act
requiring the MAHs to report in case they are not able to
supply7, but without any association with a concrete formal
definition. A similar situation was found in Norway, where
there is also no formal definition; a temporary disruption of a
medicine’s marketing was de facto considered to be a shortage
as soon as it lasted for at least 2 weeks. In the Croatian
legislation, the closest term in meaning related to drug shortages
is “disturbance on the medicines’ market.” Drug shortages are
not formally defined in Israel, but various health care institutions,
including Health Maintenance Organizations (HMO) or private
pharmacies, define shortages according to their own needs. For
example, in the Clalit Health Services (the largest state-mandated
HMO), shortages are considered as a stock covering <1 month’s
expected consumption, whilst for other institutions it might be
different, depending on the profile of customers, their needs,
and logistical considerations. Similarly, in Switzerland, the four
major public and private organizations gathering information
on drug shortages and bottlenecks in the supply of drugs
use different descriptions of drug shortages, depending on the
mission and strategic goals of these organizations. Consequently,
these definitions are associated with focusing on restricted, as
compared to usual, availability (as in case of the Federal Office
of Public Health—FOPH); the essential role in pharmacological
treatment (Swiss Agency for Therapeutic Products—Swissmedic,
i.e., the state drug registration agency, as well as the Federal Office
for National Economic Supply—FONES); the duration of the
disruption exceeding 14 days and lack of availability of all doses
and package sizes (FONES); or supplies not satisfying demand
and orders (Martinelli Consulting)8, 9, 10, 11.
7Hungarian Parliament. Act XCV/2005 (IDRAC 105308) on HumanMedicines and
the Amendment of Other Acts Regulating the Pharmaceutical Sector (“Medicines
Act”).
8Federal Office of Public Health (FOPH). Available online at: https://www.bag.
admin.ch/bag/en/home/themen/mensch-gesundheit/biomedizin-forschung/
heilmittel/sicherheit-in-der-medikamentenversorgung.html
9Federal Office of National Economic Supply (FONES). Available online at: https://
www.bwl.admin.ch/bwl/en/home.html
10Martinelli Consulting. Available online at: http://www.drugshortage.ch/index.
php/uebersicht-2/
11Swiss Agency for Therapeutic Products − Swissmedic. Available online
at: https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-
surveillance/out-of-stock.html
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According to the respondents, drug shortages have been
occurring in all of the studied countries throughout the last
decade, and typically have been increasing. This is similar to the
situation in the USA (United States Government Accountability
Office Report, 2014). Drug shortages were often reported as
“always present,” with a starting point difficult to set in time.
For some countries, the following breakthrough timeframes or
starting points of the problem have been elicited from the
respondents as: the early nineties of the twentieth century
(Estonia, Montenegro, Serbia, Slovenia), 2006 (France), around
2007 (Greece, Switzerland), between 2009 and 2011 (Austria,
Slovakia), between 2011 and 2012 (Spain), 2012 (Hungary,
Poland), 2013 (Italy), and 2015 (Azerbaijan, Israel).
In Albania, the drug shortages in the past (especially until the
early 1990s) were a much more serious problem than nowadays;
being a consequence of structural issues characterizing the
centralized pharmaceutical market. In Azerbaijan, where there
is no compulsory health care insurance (planned for the near
future), but the state provides state hospitals and 25 (out of 2,240)
preferential pharmacies executing state programs with necessary
medicines, the list of publicly funded medicines is approved by
the Ministry of Health (MoH) and the problem of shortages does
not pertain to this list. However, shortages have been noted in the
case of medicines distributed in the private sector in Azerbaijan.
The description of the situation in Kosovo is complicated since,
due to the war of 1999 and donations from different sources,
drugs were being initially registered through the provisional MA
procedure, replaced in 2006 by the regular MA at the Kosovo
Medicines Agency. Nevertheless, there are still a certain number
of medicines without MA (due to the small size of the country,
very limited budget and spending for health care) and, as such,
drug shortages are still evident in Kosovo. As a result of further
changes in the legislation, drug shortages started decreasing from
2013 and the formerly very poor situation is now improved.
The dynamics of medicines shortages in the past 3 years
have been reported very differently for the studied countries.
These were increasing in France, Greece, Italy, Latvia, Lithuania,
Norway, Ireland, Israel, Slovakia, Switzerland, and Turkey,
slightly increasing in the Czech Republic, while remaining stable
in Croatia, Serbia, and Estonia. In the latter two countries, as
well as in Hungary, the problem started to be more intensely
reported during the past 3 years for administrative reasons, so it
is not clear to what extent the shortages were really increasing
and to what extent their reporting more accurately reflected
an existing situation. In Belgium, the increased awareness of
MAH on reporting drug shortages was in parallel with the
increased reporting of hospital pharmacists and direction of
shortages’ trend, which seemed to be increasing. The drug
shortages’ dynamics were formerly increasing, but have recently
decreased, in Poland and Spain, and have been decreasing in
Slovenia. In Austria, Albania, Azerbaijan and the Republic of
Srpska (Bosnia and Herzegovina; BIH) and Montenegro, the
dynamics were characterized as difficult or impossible to assess,
while remaining unclear but reported cautiously (because of
the potential reporting bias mentioned above) as increasing in
Hungary.
Information Systems and Vigilance Related
to Drug Shortages
The existence of publicly available databases on drug shortages
has been reported from the majority of studied countries, while
in some countries access to the gathered information was not
fully open or was limited to the public (Albania, Azerbaijan, the
Czech Republic, Montenegro, and Serbia). Apparently, publicly
available databases exist in almost all of the studied EU/EFTA
countries, except for the Czech Republic. Therefore, also the
quality of any publicly revealed statistics on drug shortages in
the Czech Republic is described as difficult to assess and drug
shortages are not analyzed systematically. In Turkey, information
on shortages of medicines used only in hospital settings, is made
available only to the selected relevant stakeholders and only part
of the registry is made publicly available. In Albania, information
on shortages can be made available to a requesting party—
but only on special demand. Full information on the publicly
available databases on drug shortages (including the frequency
of their updating and other characteristics that were identified in
the studied countries) can be found in Tables 1, 2. The highest
number of publicly available databases (four) was revealed in
Switzerland. The content of these databases was found to be
differentiated depending on the purposes set by the organizations
running these databases.
In countries without national reporting systems, the evidence
is dispersed and gathered independently by various stakeholders
for their own purposes. For example, in Montenegro, this
evidence exists fragmentarily at pharmaceutical companies or
MAHs, wholesalers, pharmacies, Agency for Drugs and Medical
Devices, MoH, and the Health Insurance Fund, among others.
Information on shortages in Montenegro is not gathered
systematically, but rather in situations when a more serious
threat to continuity of care could be expected. In such cases
it is the Agency for Drugs and Medical Devices and the
MoH which are responsible for gathering this information.
In those studied countries where reliable statistics exist, the
assortments of medicines in short supply were generally well-
recognized, and there was relatively accurate information on
these. In Malta, the information on specific drug shortages was
published only for publicly reimbursed medicines. Overall, the
frequency of shortages of concrete medicines and their durations
were described as “variable,” “rather not known precisely,” and
“unpredictable.”
In almost all the countries, there exist formal obligations
of pharmaceutical companies or the MAH to notify a certain
organization or institution (“information hub”) in all or the
majority of the following cases: (a) delayed or postponed
commercialization of a medicinal product; (b) suspension,
withdrawal, or lack of renewal of MA; (c) the predicted or sudden
unavailability of a medicinal product due to other reasons; (d)
the ceasing of reimbursement of a medicinal product; or (e) in
other cases which could lead to drug shortages. The exemptions
are Kosovo and Azerbaijan, but in the latter, although formally
there is no such obligation specified in the legislation, such
notifications are voluntary. Interestingly, in Norway the MAHs
are not only obliged to notify the competent authorities but
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TABLE 2 | Publicly available databases on drug shortages in countries outside of the area of the European Union and the European Free Trade Association.
Country Organization in charge of
database
Access Frequency of database
updating
Notes
Israel Ministry of Health www.health.gov.il According to the need Database known as “Warnings on Medications and
Cosmetics Website; Notices of Medicines Marketing
Interruptions.”
Kosovo Kosovo Medicines Agency www.akppm.com – –
Republic of
Srpska, Bosnia
and Herzegovina
The Agency for Medicinal
Products and Medical Devices of
Bosnia and Herzegovina
(ALMBIH)
http://www.almbih.gov.ba/
vijesti/
As soon as the ALMBIH is
informed by the MAH about
shortage of a given medicine
Information available under the section “News” on
the ALMBIH internet site. Information on temporary
shortages of medicines is provided to the ALMBIH
by the appropriate MAH, including with reasons and
expected date of availability.
Turkey Turkish Medicines and Medical
Devices Agency: TMMDA (in
Turkish: Türkiye Ilaç Ve Tibbi
Cihaz Kurumu; TI˙TCK)
http://www.titck.gov.tr/ Weekly Only a part of the registry is made publicly available.
TI˙TCK collects data on shortages by using the
Pharmaceutical Track and Trace System to detect
which medications are not available at the
pharmacy level. If the stock of medication is below a
certain level at the pharmacies (depending on the
type of medication and whether it’s an orphan or
non-orphan status, etc.) it is labeled as passive.
Similarly, a drug’s statuses such as canceled,
authorized, suspended, etc. are also labeled as
passive. The list is integrated with e-prescription
software that prohibits physicians from prescribing
medicines which are unavailable. The list focuses on
medicines used in out-patient settings.
are expected to notify patient organizations on foreseen or
existing drug shortages, although this is not required by law. In
countries where reporting systems exist, at least one institution
per country was included in the national reporting system,
usually the national ministry responsible for health affairs or the
agency responsible for the authorization of medicines. Moreover,
in the majority of countries there was at least one additional
institution (another hub) involved in gathering information,
although in some countries (e.g., Belgium, Estonia, Poland)
information was gathered by one institution but then further
shared with others. The names of all the organizations involved in
gathering information on drug shortages, including the main and
additional ones which were identified in the studied countries,
can be found in Tables 3, 4.
“Bottom-Up” Initiatives
In some countries, bottom-up initiatives were undertaken such
as working groups or informal networks targeted to tackle
the problem of drug shortages; as well as guidelines, codes
of conduct, good practices, or management plans related to
drug shortages were also elaborated. These initiatives included
establishing a working group at the hospital pharmacists’
association and voluntary reporting of pharmaceutical
companies to the pharmacists’ publisher (Austria), or creating
informal networks or committees tackling the problem of drug
shortages (Czech Republic). Standard Operating Procedures
for managing drug shortages were developed at the national
institution responsible for drug registration in Estonia. In
Belgium, a taskforce led by FAMHP and the National Institute
of Health and Disability Insurance (NIHDI) was set up. The
taskforce aims to prevent drug shortages through devising
measures aimed at preventing drug shortages and minimizing
the impact on patients through acting proactively on notifications
of reported drug shortages and similar activities. In Belgium, the
involvement of all umbrella organizations (such as the branded
and generic industries, wholesalers, hospital pharmacies,
community pharmacies, and insurance organizations) is
considered essential to mitigate the problem of drug shortages.
Surveillance and inspections were considered as important
practices aimed at mitigating the problem of drug shortages in
many of the studied countries.
In Hungary, a clearly outlined, step-by step practical guidance
for health providers has been issued by the Professional College
of Health Care (serving as an advisory body to the State Secretary
of Health Care) on how to react in the case of drug shortages. It
includes the following key areas: (a) preparing a strategic plan on
tackling shortages; (b) contacting wholesalers and manufacturers
to estimate the duration and severity of the drug shortage; (c)
determining alternative treatments; (d) estimating the impact of
the shortages on health and costs of treatment; (e) estimating the
current stock of drugs affected by the potential shortage warning;
(f) implementing official guidance on identifying and approving
alternative treatments; (g) securing communication and patient
safety; (h) collaborating with other external stakeholders; and (i)
implementing prioritization among patients12.
In Norway, a hospital pharmacy working group was formed
in Oslo to deal with drug shortages on behalf of all the hospital
regions. They conduct weekly meetings, with representatives
12Hungarian Professional College of Health Care. Recommendations to Treat Drug
Shortages (in Hungarian). Available online at: http://www.mgyt-kgysz.hu/index.
php?option=com_docman&task=doc_download&gid=224
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TABLE 3 | Organizations involved in gathering information (“information hubs”) on drug shortages in countries of the European Union and the European Free Trade
Association.
Country Main organization Additional organizations Notes
Austria Austrian Medicines and Medical Devices
Agency (AGES MEA)
• Main Association of Austrian Social
Insurance Institutions (MAASSI)
• Pharmacists’ Publishing House (http://
warenverzeichnis.apoverlag.at/)
MAASSI does not publish information on shortages, but
keeps track of shortages affecting reimbursed medicines, as
drugs which are not available for longer periods will be
delisted.
The database of the Pharmacists’ Publishing House requires
payment to access.
Belgium Federal Agency of Medicines and Health
Products (FAMHP)
• National Institute of Health and Disability
Insurance (NIHDI; Dutch abbr. RIZIV; French
abbr. INAMI); i.e., the Belgian national health
insurance fund
FAMHP informs NIHDI of reported shortages of reimbursed
medicines only.
Croatia Croatian Health Insurance Fund • Croatian Agency for Medicinal Products and
Medical Devices (HALMED)
Information gathered by HALMED is limited to products with
ceased or not prolonged registration, stopped production, or
importation (i.e., situations not necessarily considered
shortages, according to some deﬁnitions).
Czech
Republic
State Institute for Drug Control (SUKL) • Ministry of Health (Department of State) Information gathered by both organizations is limited to
suspended products (i.e., situations not necessarily
considered shortages, according to some deﬁnitions).
Estonia Estonian State Agency of Medicines
(ESAM)
• Estonian Health Insurance Fund (EHIF) ESAM uses information derived from prescriptions, which is
gathered by EHIF, to assess the need for products.
France French Agency for Medicines Safety
(ANSM)
• Regional health agencies (Agences
régionales de santé—ARS)
• National Council of the College of
Pharmacists (Conseil national de l’ordre des
pharmaciens—CNOP)
–
Greece National Organization for Medicines
(EOF)
• Pharmacists’ associations The pharmacists’ associations independently gather some
information, but their data on shortages cannot be considered
comprehensive or reliable (to the contrary of EOF’s data).
Hungary National Institute of Pharmacy and
Nutrition
• National Institute of Health Insurance Fund
Management (NIHIFM)
• Wholesalers
NIHIFM needs to be notiﬁed only in the case of a drug
shortage of reimbursed products.
Ireland Health Products Regulatory Authority
(HPRA)
• Irish Pharmaceutical Union
(IPU)—professional body of community
pharmacists
• Wholesalers
The notiﬁcation of HPRA is non-obligatory yet. The
wholesalers keep track of current shortage situation to allow
them to keep pharmacies informed.
HPRA manage and approve “Batch Speciﬁc Requests.”
HPRA may consider a batch-speciﬁc request application from
a MAH in order to ensure the continued availability of a
medicine on the Irish market.
Italy Italian Medicines Agency (AIFA) • Regional health authorities –
Latvia State Agency of Medicines of Latvia
(SAMLV)
• Health Inspectorate
• National Health Service (NHS)
Information gathered by the NHS is limited to reimbursed
products only.
Lithuania State Medicines Control Agency • No other organizations –
Malta Medicines Intelligence and Access Unit,
Malta Medicines Authority (MMA)
Central Procurement and Supplies Unit (CPSU),
Ministry for Health (covers medicines supplied
through the national public health system)
The Medicines Intelligence and Access Unit is responsible for
managing a proactive and targeted approach to enhance
medicines’ intelligence and access. It supports the health
care industry and all stakeholders in accessing medicinal
products.
Norway Norwegian Medicines Agency (NoMA) • Wholesalers –
Poland State Pharmaceutical Inspection • Ministry of Health Full information on drug shortages is gathered by the State
Pharmaceutical Inspection.
Portugal Ministry of Health • INFARMED—National Authority of Medicines
and Health Products
• ANF—National Association of Pharmacies
• CEFAR—Center for Health Research and
Evaluation
–
Slovakia The State Institute for Drug Control • Ministry of Health
• Health Insurance Fund
• The Slovak Chamber of Pharmacies
Information gathered by all Slovak organizations involved in
gathering information on drug shortages is limited to
reimbursed products only.
(Continued)
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TABLE 3 | Continued
Country Main organization Additional organizations Notes
Slovenia Agency for Medicinal Products and
Medical Devices
• Pharmacy Chamber of Slovenia
• Trade Chamber
–
Spain Spanish Agency of Medicines and
Health Products (AEMPS), being part of
the Spanish Ministry of Health
• Center for Information on Medicines Supply
(in Spanish: Centro de Información sobre el
Suministro de Medicamentos; CISMED)
• Databases run independently by
governments of Autonomous Regions of
Spain
Database of the governmental agency AEMPS contains
publicly available but raw information on drug shortages,
without any secondary analyses.
Database of CISMED, created by pharmacists’ professional
organization—Collegiate Pharmaceutical Organization (in
Spanish: Organización Farmacéutica Colegial) contains more
complex information but is not disclosed to the public.
Switzerland Swissmedic (Swiss Agency for
Therapeutic Products) and Federal Ofﬁce
of National Economic Supply (FONES)
• Manufacturers and other enterprises
• Wholesalers
• Professional organizations (e.g., hospital
pharmacists’ association GSASA)
• Hospitals, long-term care institutions for the
elderly, etc
–
of the Norwegian Medicines Agency (NoMA) attending at
least once a month or when needed. NoMA has also formed
an internal “shortage team” consisting of pharmacists and
physicians. This team assesses notifications and takes care of the
majority of situations on an ongoing basis. In the case of more
severe or complex shortage situations, the team might summon
dedicated persons from several departments of NoMA to form an
extended advisory group. The teamwork across the departments
includes, for example, the Inspectorate responsible for “rapid
alert” notifications and close contacts with NoMA representatives
in international organizations, such as the Committee for
Medicinal Products for Human Use or the Pharmacovigilance
Risk Assessment Committee of the EMA, as well as the Co-
ordination group for Mutual recognition and Decentralized
procedures—human (CMDh), which originated at the network
of the Heads ofMedicines Agencies. This involvement has helped
to ensure that situations occurring at EU level are handled in
an efficient manner. In addition, NoMA has developed a wide
and well-functioning national collaboration with the various
stakeholders, in order to find appropriate country-wide solutions.
While in Norway the bottom-up initiative was started by
hospital pharmacists, in Ireland the Irish Pharmaceutical Union
(the professional body representing 95% of Irish community
pharmacies) created an online platform providing up-to date
information on drug shortages13. This was generally deemed to
be a reliable source of information by the Irish pharmacists.
Numerous bottom-up initiatives and innovations within
organizational frameworks aimed at coping with or preventing
drug shortages have been developed in Spain. Due to the
lack of precise information on shortages, the Center for
Information on Medicines Supply (abbreviation in Spanish:
CISMED) was created in 2014, as a bottom-up initiative of
the Spanish pharmacists’ professional organization (Collegiate
Pharmaceutical Organization)14. It contains information on
13The Irish Pharmacy Union. Available online at: https://ipu.ie/home/
14General Council of Provincial Pharmacy Chambers. CISMED Database - Center
for Information on Medicines Supply (in Spanish: Centro de Información sobre
el Suministro de Medicamentos; CISMED). Available online at: http://www.
shortages that is voluntarily provided by pharmacists from across
the whole country, as well as detailed reports and analyses on
the shortages. The database of CISMED is run independently
from the governmental database of the AEMPS15. Similarly,
in Switzerland, in response to existing but unsatisfactory
governmental efforts in the area of drug shortages prevention
and information, a chief pharmacist at a regional hospital has
successfully established an independent database, gathering alerts
mainly from other hospital pharmacies in the country. Currently,
this database receives by far the highest number of notifications
as compared with the other Swiss drug shortages databases. For
example, it receives ten times the number of notifications than
the official governmental database run by the Federal Office of
National Economic Supply (FONES), which gathers information
only on disruptions in supply of medicines considered as
“essential,” lasting for more than 14 days, and pertaining to the
lack of presence of all registered doses and package sizes (i.e.,
shortages of selected doses and package sizes are not included as
long as other doses and sizes are still available)8.
In Montenegro, some non-governmental organizations
(NGO) and associations of patients with certain diseases (e.g.,
HIV-positive individuals) have started to tackle the problem
of drug shortages, continually appealing through the mass
media, social networks, and other ways of communication for
potential solutions for drug deficiencies and shortages, with
special attention paid to certain particularly sensitive groups of
patients. In Serbia, occasional press publications appear, initiated
by patients’ organizations and aimed at raising awareness on
drug shortages.
In Slovakia, in addition to the governmental organizations
involved in gathering information on drug shortages, the
Chamber of Pharmacies (Slovenská Lekárenská Komora—SLK)
runs a drug shortages database and independently monitors
portalfarma.com/Profesionales/consejoinforma/Paginas/Infarma-2016-CISMED.
aspx
15Spanish Agency of Medicines and Health Products. AEMPS Database.
Available online at: https://cima.aemps.es/cima/fichasTecnicas.do?metodo=
buscarDesabastecidos
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TABLE 4 | Organizations involved in gathering information (“information hubs”) on drug shortages in countries outside of the area of the European Union and European
Free Trade Association.
Country Main organization Additional organizations Notes
Albania National Agency of Drugs and
Medical Devices
• Health Insurance Fund –
Azerbaijan Center for Analytical Expertise of
Medicines of the Ministry of Health,
• Ministry of Economic Development –
Israel Ministry of Health • All four national Health Maintenance
Organizations (HMO): Clalit Health Services,
Maccabi Healthcare Services, Meuhedet
Health Services, and Leumit Health Services
Access to the database of the Ministry of Health is open to
the public. The other databases are shared only with certain
employees of a given organization.
Kosovo Kosovo Medicines Agency • Pharmaceutical Chamber of Kosovo
• Pharmaceutical Society of Kosovo
–
Montenegro Montenegrin Agency for Drugs and
Medical Devices
• Ministry of Health
• Wholesalers
Information gathered by the Montenegrin Agency for Drugs
and Medical Devices embraces all medicines marketed in
Montenegro. The Ministry of Health gathers information only
on medicines which are reimbursed by the Montenegrin
Health Insurance Fund. All this information pertains to a rather
more serious potential threat to continuity of care, since in the
ofﬁcial regulation it is not explicitly stated that information on
drug shortages has to be reported in Montenegro.
Republic of
Srpska, Bosnia
and Herzegovina
(BIH)
Agency for Medicinal Products and
Medical Devices of BIH
• Ministry of Health and Social Welfare of the
Republic of Srpska
• Health Insurance Fund
• Public Health Institute
Informing organizations which are listed as additional is
non-obligatory for the MAH, nevertheless performed in
practice. These institutions do not publish this information,
but they are rather informed in order to take steps within their
competence.
Serbia Republic Health Insurance Fund
(RFZO)
– Information on medicines shortages is usually provided on a
weekly basis by hospital pharmacists from the secondary and
tertiary health care level. No feedback is provided by the
RFZO on potential dates when shortages are expected to be
resolved.
Turkey Turkish Medicines and Medical
Devices Agency
(TI˙TCK)—Department of Economic
Assessments and Drug Supply
Management
• Turkish Pharmacists Association (TPA)
• Social Security Agency (SSA)
The Department of Economic Assessments and Drug Supply
Management is responsible for gathering information on
shortages, managing prices of medications, contributing
reimbursement decisions, and supplying unlicensed
medications to patients and HTA. The MAH is responsible for
notifying this department for shortages, possible stock
problems, etc. Alerts can also be obtained from the public,
physicians and pharmacists and wholesalers via various
channels. There is a registry system for shortages; this
registry is not publicly available, but it is shared with relevant
organizations such as the SSA. This unit also undertakes
measures to tackle and prevent shortages in collaboration
with other health authorities, NGOs like TPA, and MAHs.
and analyzes the situation in pharmacies. It actively informs
pharmacies on actual drug shortages and cooperates with the
State Institute for Drug Control and the MoH.
Initiatives in several countries have also included the
imposition of quotas by wholesalers on sales to pharmacies. In
Belgium and some other countries, the efforts to limit parallel
exports have been initiated by the MAH via the imposition
of quotas on orders of medicines, having a further impact
(domino effect) at subsequent levels of trade. Paradoxically,
quotas—although introduced in order to provide stable supplies
of medicines in or at risk of shortages—contribute to the overall
picture of shortages in many countries, especially impacting on
health care facilities or patients whose access to medicines can
be limited due to these quotas. Pharmaceutical companies in
Lithuania sometimes create special schemes for their products,
selling them only to selected pharmacies or having an agreement
only with certain wholesalers, thus trying to protect their
medicines from parallel export. Quotas in Poland were reported
to be associated even with special verification of pharmacy orders
by wholesalers requiring prescription scans from pharmacies.
Other Initiatives and Organizational
Frameworks
In 2007, the Spanish Ministry of Health launched the
“Coordinated Program of Control of Drug Supply” associated
with a computer application called SEGUIMED (monitoring
supply of medicines in the domestic market), which allows for
making queries and reports on the status of distribution of
medicines from when they leave the manufacturing plant until
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they are dispensed in pharmacies16. In this way, coordination
among all the agents involved in the trade is facilitated,
although the application was criticized by organizations
representing major pharmaceutical distributors (FEDIFAR) as
being obsolete17. In response to the communication of a supply
problem, the AEMPS first assesses the possible impact that
lack of supply could have on Spanish citizens. If this poses a
threat to the citizens’ health, it starts a series of measures aimed
at resumption of supply and keeps health authorities of the
Autonomous Communities informed. Besides administering
a database on drug shortages, since 2009 the AEMPS also
publishes information on its website on possible alternatives to
the medicines in short supply. Furthermore, in some situations of
shortages the AEMPS actively searches for medicines of foreign
origin that could serve as alternatives to a nationally-produced
medicine that is currently out of stock and it also authorizes
its importation (Desabastecimientos de Medicamentos: Un
Problema Sin Resolver, 2015). As mentioned, this is different to
the CISMED initiative, which was developed to improve current
knowledge.
A working group designed to assess severity of medicine
shortages and propose actions was also set up by the National
Organization for Medicines (EOF) in Greece. Moreover, one of
the responsibilities of the Institution of Pharmaceutical Research
and Technology, being a subsidiary of the EOF, is to cover
demand when a given drug is in short supply, or its marketing
has been discontinued. It includes searching for medicines on
the international market outside of Greece, especially in case of
medicines considered as unique or irreplaceable.
The State Medicines Agency in Latvia (SAMLV) has
established a “Rapid alert working group,” taking decisions on
necessary actions in cases of a detection of quality defects in
medicinal products (including the appearance of counterfeit
medicines)18.
Although the MAH is formally obliged to inform the State
Medicines Control Agency (SMCA) in Lithuania, quite often
this obligation is not fulfilled in practice. Therefore, the Head
of the SMCA issued an order in 2012 aimed at combating
drug shortages, according to which wholesalers send weekly
reports to the SMCA on stock availability on the market.
The SMCA experts analyze all the stocks which are reduced
to a low level, highlighting medicinal products, places where
potential shortages could appear, and checking if the reports of
shortages were published by the MAH. When the information
on the shortages is confirmed, the public is informed through
the SMCA website both on the shortage of a particular
medicinal product and the possible substitutes currently available
on the market. Moreover, if a medicinal product of high
16Spanish Ministry of Health. SEGUIMED. Available online at: http://www.
seguimed.es/seguimed-software-gestion-abastecimiento-medicamentos.html
17ELGLOBAL.NET. El Seguimed es un sistema de control que está obsoleto.
Available online at: http://www.elglobal.net/hemeroteca/el-seguimed-es-un-
sistema-de-control-que-esta-obsoleto-FYEG_888841
18Latvian Cabinet of Ministers. Regulation No 416 of the Cabinet of Ministers of the
Republic of Latvia “Procedures regarding the Distribution and Quality Control of
Medicinal Products” (adopted on 26 June 2007). Available online at: https://www.
zva.gov.lv/?id=382&sa=382&top=333
importance (e.g., vaccine or reimbursed product) is in short
supply, the SMCA immediately informs the MoH and the
National Health Insurance Fund via an official note and attempts
to find a solution. This includes, for example, finding and
importing substitutes from other countries or negotiating higher
production and supply levels with other retailers. Subsequently,
the SMCA informs the public on the agreed solution, and the
availability of the drug in short supply and its substitutes.
The MoH in Israel manages a drug shortages database, known
as the “Notices of Medicines Marketing Interruptions.” They also
send e-mail alerts to every registered health care provider in
the case of some shortages, with an estimation on when they
are supposed to be resolved. Israel’s MoH has also published
the procedure according to which every drug supplier must
declare an expected drug shortage at least 3–6 months before it
actually happens. In the case of serious problems arising from a
shortage and fear for public health (for example if a drug fails
to meet the Good Manufacturing Practice guidelines) the drug
supplier must follow the European directive which defines this
situation as urgent (Israel’s Ministry of Health - Pharmaceutical
Administration, 2011).
In Turkey, in order to prevent or cope with problem of drug
shortages, the national medicines agency TI˙TCK (responsible
for, among others, taking the necessary precautions to ensure
that vital medications, medical devices, and health products are
constantly available on the market) established the Department
of Economic Assessments and Drug Supply Management in
201219. This department is responsible for registering drug
shortages, managing stocks, taking necessary actions to solve
shortages-related problems or preventing them in the future,
and notifying the relevant stakeholders such as the Turkish
Pharmacists Association. It is also responsible for managing the
prices of medications (so they can intervene if the shortage
is dependent on the price), supplying unlicensed medications
from other countries if necessary, and giving priority to certain
medications when licensing them.
In Azerbaijan, in order to gather information on drug
shortages directly from patients, a hotline was established at the
Center for Analytical Expertise of Medicines of the Ministry
of Health. A special commission was also set up at the MoH,
one of the tasks of which is to monitor drug shortages. All the
information on the shortages of medicines is then transferred to
the Ministry of Economic Development.
Influencing Trade Rules (without a Direct
Impact on Arbitrage/Parallel Trade)
Measures aiming to mitigate or prevent drug shortages in the
various countries involved in this study, influencing trade rules
but not having a direct impact on arbitrage or parallel trade, were
associated mainly (but not exhaustively) with the approach to
public service obligations (PSOs) and the possibility to prescribe
medicines which were not registered in a particular country.
PSOs associated with supplying medicines to cover patients’
needs, so as not to compromise patient care, exist in the majority
of studied countries. However EU legislation, and the way this
19Turkish Minister of Health. Regulation: KHK/663; Item 27/Clause 2/Article d.
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is transposed into the national legislation of EU countries, opens
a doorway to increased transparency. According to Article 81 of
Directive 2001/83: “The holder of a marketing authorization for
a medicinal product and the distributors of the said medicinal
product actually placed on the market of a Member State shall,
within the limits of their responsibilities, ensure appropriate and
continued supplies of that medicinal product to pharmacies and
persons authorized to supply medicinal products so that the
needs of patients in the Member State in question are covered20.”
Interestingly, the PSOs have been implemented also in several
non-EU states. For example, in Turkey the PSO is stated as
follows: “MAHs are responsible to provide market availability for
their licensed products” and “MA can be canceled if the MAHs
cannot manage to supply their products to the market19.”
In the majority of studied countries, the PSO could embrace
all registered products, although in Poland it is more strongly
expressed or followed more carefully in the case of reimbursed
products. In Croatia, Italy, Slovakia, and Serbia, it is limited
to publicly reimbursed products only. In Albania, the PSO is
specific to products which can be reimbursed or bought directly
by the state, as part of specific reimbursement lists, or products
included into public hospitals drug lists. As soon as the PSOs are
in place, they are formulated within a given country’s legislation,
with the exception of Estonia. The pharmaceutical companies
in Poland are obliged to declare a certain volume of sales for
each year of the reimbursement decision’s duration, and they are
expected to pay fines in the case of shortages. In Montenegro,
the PSO pertains to providing continuous supply of medicines
rather than covering the needs of the country’s population, and in
the case of reimbursed medicines—to providing their availability
to the insured persons. The PSO in Slovakia is associated with
timeframes within which the MAHs and wholesalers are obliged
to deliver medicines included in the national reimbursement list–
24 and 48 h, respectively, from receiving an order for a given
medicine. On the other hand, a pharmacy is obliged to accept
delivery of the ordered medicine from the wholesaler within
24 h from placing their order (Slovak Parliament, 2011). We
identified a very special approach to PSO in Switzerland, where
60 medicines considered by health authorities as essential and
of the highest importance to public health (regardless of their
reimbursement status) must to be stockpiled by manufacturers,
but the conditions are negotiated and set in agreements between
them and FONES8. PSOs do not exist in Azerbaijan and Kosovo.
Typically in smaller countries, local authorities can find
it difficult to enforce PSOs. The authorities try to motivate
pharmaceutical companies to register products rather than
making them delist these products. Consequently, in some cases
enforcement of PSOs can have a negative effect on availability
since it can backfire e.g., if a product is delisted, it cannot even be
parallel imported. Countries with small pharmaceutical markets
can in some cases provide solutions aimed at mitigating possible
problems associated with supplying them with medicines and
facilitating trade. For example, in Albania, an additional adhesive
20European Parliament. Directive 2001/83/EC of the European Parliament and of
the Council of 6 November 2001 on the Community code relating to medicinal
products for human use.
label with information in Albanian language can be placed
onto the original outer packaging. This is the case in situations
including the supply of first alternative drug or drugs for hospital
use, where the quantity does not exceed 4 months’ supply, or
when a given drug constitutes the only alternative treatment
available on the market. This is to avoid delays in the market
supply21.
One of the possible remedies in the case of drug shortages
is the possibility for physicians to prescribe an unlicensed
medicine if a registered product is unavailable on the market.
In the EU Member States, this refers to the possibility of use
of Article 5 of Directive 2001/83/EC, and the prescribing of
medicinal products without a MA under Article 5 still requires
some form of authorization by the national authorities20. Such
alternative options are formally available to physicians in all
studied countries. Obtaining a special permit or exemption from
the responsible state authorities is usually necessary in such cases.
In Hungary, there are several administrative obstacles (including
the special individual approval of the National Institute for
Pharmacy and Nutrition) to prescribing an unlicensed medicine,
although such an option is formally allowed. In the case of
drug shortages with expected severe consequences, a so-called
“contingent approval” to import a larger amount of non-
registered products may be given to wholesalers to bypass the
bureaucratic impediments of individual approval7. In Ireland, the
granting of a temporary authorization for a batch of a medicine
which is not registered but necessary for patients, is based on
a “batch specific request,” reviewed by the Health Products
Regulatory Authority (HPRA) (Health Products Regulatory
Authority, 2017). Such applications may be appropriate when
a medicine in full compliance with its registered MA dossier is
temporarily unavailable or where action is proposed to bring a
batch into compliance with the registered details.
Similarly, the possibility for pharmacies or wholesalers to
import unlicensed medicines is available in a majority of
European countries. In France, a medicinal product must be
in any case authorized by the French Agency for Medicines
Safety (ANSM) to be imported either by a standard MA,
by a temporary use authorization, or a specific authorization.
Importation authorizations are restrictive in France; they are
delivered for a maximum of 1 year and for a fixed volume.
Belgian pharmacies can import such medications only in the case
of a shortage of an equivalent product being confirmed by the
FAMHP and a physician’s declaration is provided stating that
a medicine is actually necessary for a patient. In Switzerland,
the importation permits for unlicensed medicines are issued by
Swissmedic, the national drug registration agency.
In BIH, the MoH of the Republic of Srpska or the MoH of the
Federation of BIH (the two political entities that compose BIH)
may authorize the import of a medicine without a MA issued
by the Agency for Medicinal Products and Medical Devices of
BIH. It can happen only in cases of an urgent, medically justified
need of a particular patient or the need of using limited quantities
of medicines which are necessary for the population’s health
protection. In both situations, the application must be issued by
21Albanian Council of Ministers. Bylaw no. 299 08.04.2015.
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the health facility. The import permit given to wholesaler may be
authorized only in case of unavailability of a medicine with MA
(The Parliamentary Assembly of Bosnia Herzegovina, 2008).
In Montenegro, the possibility to prescribe an unlicensed
medicine plays an extremely important role. Due to a small
market size, the country is encountering a lack of interest in the
registration procedure and, as a result, ∼20% of medicines are
being placed on the market via the special import procedure,
based on the Law on medicines (Government of Montenegro
- Ministry of Health, 2011). In such cases, the Agency for
Drugs and Medical Devices grants an import license for non-
registered medicine(s) to a wholesaler, which will import that
medicine(s) and deliver it to a given health institution or
pharmacy. This is important for specific patients or groups of
patients who need such particular medicines and cannot be
adequately treated with medicines registered on theMontenegrin
market. Moreover, importing medicines from countries with
very similar official languages as Montenegrin (Serbia, Croatia,
Bosnia andHerzegovina), following approval of theMontenegrin
Agency for Drugs and Medical Devices, which is based on
registration issued in these countries, facilitates supplying the
national market and assists in preventing drug shortages. This
simplified approach becomes invalid when differences exist in the
documentation betweenMontenegro and these countries and the
labeling has to be clearly specific for Montenegro.
In order to cope with severe supply problems and shortages
of medicines in Kosovo, several changes were made to the
legislation to allow for the import of products without MA. As
a result, if there are no products identified by their International
Non-proprietary Name and pharmaceutical form and which have
MA issued in Kosovo, then wholesalers can import them from
any of the EU Member States. This was implemented to ensure
that the appropriate national authority has already considered
the quality issues. A similar procedure is followed when a given
product has obtained MA but is not present on the market—in
such a case the national Agency can suspend MA for a given
period and permit the import.
Several innovative practices have originated in Malta, where
the specifics of this small-sized national pharmaceutical market
prompted the authorities to use a number of measures available
under EU legislation. This especially included implementation
of Article 126a of Directive 2001/83/EC, enabling authorizing
the placing of a medicinal product with a MA in another EU
Member State on the Maltese market in the absence of a MA or
of a pending application in Malta20. There have also been other
measures implemented, including that medicinal products could
be placed on the market in any one of the official languages of
Malta (i.e., Maltese or English), or accepting the possibility of
having joint packs with other larger English-speaking countries,
mainly the UK and/or Ireland (Vella Bonanno and Gavril,
2011). The issuing of some authorizations for distribution of
unauthorized medicines based on Article 126a of the Directive
2001/83/EC was also reported from Latvia22.
22State Agency of Medicines of the Republic of Latvia. Available online at: https://
www.zva.gov.lv/?id=513&lang=&top=112&sa=377
Last but not least, in Hungary, for some key products
the National Institute for Pharmacy and Nutrition asks for
stock reports from wholesalers, manufacturers, and hospitals
to prevent shortages. In the case of generics, where internal
reference pricing is applied, should the continuous supply of the
lowest price (reference) product not be further guaranteed, the
preferred status of that product may be removed. In such a case,
other drugs with the lowest daily treatment cost may be awarded
the status of preferred (reference) products (Hungarian Minister
of Health, 2004).
The summary information on measures influencing trade
rules concerning medicines can be found in Tables 5, 6.
Influencing Medicines’ Trade Rules in
Response to Arbitrage/Parallel Trade
Since one of the possible reasons for drug shortages can be
arbitrage or, as it is officially referred to in the case of EU
countries, parallel export of medicines from markets where they
are relatively cheaper to markets where their prices are higher,
measures were taken in some countries to limit parallel export.
EU legislation allows for limiting parallel export if public health
in a Member State is endangered. However, not all EU countries
have introduced specific measures into their legislative systems.
In the Czech Republic, for example, the legislative changes were
approved and effective recently, in April 2017. Nevertheless,
these legislative changes mainly reflect long-term practice in this
respect, in the Czech Republic (e.g., the competence of the MoH
to communicate with exporters). In Italy, the formal possibilities
to limit parallel export temporally do exist through issuing of
the MoH’s decisions, although they have not been executed yet.
Generally, the forms of limiting arbitrage or parallel trade appear
to be highly differentiated (Tables 5, 6). In some of the studied
countries, they are made at the highest official level—through
the issuing of banning decisions by, for instance, the MoH in
Poland, the National Medicines Agency in Estonia, or jointly by
the National Medicines Agency and the Ministry of Economics
in Turkey. The possibility to limit parallel trade of medicines
in Slovenia is executed indirectly through the inspection of
pharmacies.
Since parallel export is considered by the Polish MoH as
an important issue, the crucial top-down change that was
introduced in May 2015 established a list of medicinal products,
food products for special dietary use, and medical devices
vulnerable to lack of availability on the territory of the Republic
of Poland23. Any wholesaler aiming to export a listed product
from Poland is obliged to obtain permission from the Main
Pharmaceutical Inspectorate. This legal change appreciably
reduced the problem of drug shortages, although the illegal re-
exportation (reversal of trade chain) of medicines still remains
a serious problem. It is associated with illegal practices of
pharmaceutical entrepreneurs, pertaining to prohibited trading
of medicines from pharmacies or health care facilities to
23Polish Parliament. Ustawa z dnia 12 maja 2011 r. o refundacji leków, s´rodków
spozywczych specjalnego przeznaczenia zywieniowego oraz wyrobówmedycznych
(Act of 12 May 2011 on reimbursement of medicines, food products for special
dietary use and medical devices).
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TABLE 5 | The summary information on measures inﬂuencing trade rules of the European Union and the European Free Trade Association.
Country Public service obligations:
A—pertaining to all medicines
R—limited to reimbursed medicines only
N—nonexistent
Possibility to prescribe non-registered
medicine:
Y—allowed
N—not allowed
Limitation of arbitrage/parallel export:
N—not possible
O—possible but not executed
Y—possible and executed
Austria A Y N
Belgium A Y O
Croatia R Y N
Czech Republic A Y Y
Estonia A Y Y
France A Y Y
Greece A Y Y
Hungary A Y O
Ireland A Y N
Italy R Y O
Latvia A Y N
Lithuania A Y N
Malta A Y O
Norway A Y O
Poland A Y Y
Portugal A Y Y
Slovakia R Y Y
Slovenia A Y N
Spain A Y Y
Switzerland A Y O
TABLE 6 | The summary information on measures inﬂuencing trade rules in countries outside of the area of the European Union and European Free Trade Association.
Country Public service obligations:
A—pertaining to all medicines
R—limited to reimbursed medicines only
N—non-existent
Possibility to prescribe non-registered
medicine:
Y—allowed
N—not allowed
Limitation of arbitrage/parallel export:
N—not possible
O—possible but not executed
Y—possible and executed
Albania A Y N
Azerbaijan N Y N
Israel A Y N
Kosovo N Y Y
Montenegro A Y N
Republic of Srpska (BIH) A Y N
Serbia R Y N
Turkey A Y Y
wholesalers and then exporting them. In order to eliminate
illegal practices, all Polish pharmaceutical market entrepreneurs
will have to submit detailed information on traded medicines
into a special system (the Integrated System of Monitoring
Trade of Medicinal Products) starting from 201824. The Polish
health authorities will be able to track every single package of a
medicinal product on the Polishmarket. Except for the additional
benefits expected from launching this system (e.g., increased
24Polish Parliament. Statute on Changing Statute on Pharmaceutical Law. Project
of 21.03.2017 (Polish: ustawa o zmianie ustawy Prawo farmaceutyczne. Projekt
21.03.2017). Available online at: https://legislacja.rcl.gov.pl/docs//2/12294213/
12406989/12406990/dokument283459.pdf
pharmacovigilance and safety of medicines use), it should
diminish the scale of the reversed chain of trade. Interestingly,
a specialized system for tracking medications throughout the
distribution chain (from manufacturing process to patients), the
Pharmaceutical Track and Trace System (I˙TS), has also been
developed in Turkey.When excessive export of medicines occurs,
the I˙TS allows to track it as well25.
Since relatively low prices of medicines in Poland increase
the probability of exporting them, recently the Polish MoH
also had the controversial idea of increasing official (nominal)
25 I˙TS (Pharmaceutical Track & Trace System). Turkey. Available online at: https://
itsportal.saglik.gov.tr/index.php?run=content&get=27&mp=26,33
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prices in order to bring them closer to levels from more
aﬄuent Western European countries, where they are often
much more expensive. At the same time, effective prices were
supposed to stay at their current levels through using confidential
risk sharing arrangements (instruments). Such changes were
only possible in the case of reimbursed drugs. Nevertheless,
the MoH canceled the implementation of this initiative. In
addition, in France, as in Poland, it is prohibited by law
to export medicines of major therapeutic value in case of a
drug shortage. In Greece, prohibition of parallel exporting was
imposed initially on vaccines and then also for other medicinal
products.
In Spain, several measures to prevent excessive export of
medicines have been developed. Development of distribution
activity to other countries, undertaken by pharmacies and
other entrepreneurs, concerningmedicines with supply problems
which could have an impact on health care in Spain, has
been considered to be a very serious problem since 2015
(King of Spain, 2015). Compliance with Good Distribution
Practices has been strongly required at least since 2013, including
measures aimed at preventing reverse distribution, as well
as obligatory notification of suspected drug diversions26. The
formally sanctioned priority in medicines distribution in Spain
is supplying the national pharmacies. MAHs and wholesalers
should ensure, within the limits of their responsibility and within
the agreed delivery times, an adequate and continuous supply
of medicines to Spanish pharmacies so that the needs of the
patients are covered. In cases where there are problems of
supply of medicines whose shortages may have an impact on
health care, the AEMPS will play a key role26. This pertains
to situations when: (a) it is a drug that, because of its active
ingredient, dosage or route of administration, is the only one
registered in Spain for a particular disease and its absence
generates a therapeutic gap; or (b) it is a medicinal product whose
absence implies a modification of the prescription. Under these
circumstances, the AEMPS should adopt the measures it deems
necessary to resolve this situation and may limit the export of
medicines based on the need for protection of public health, in
collaboration with the competent authorities of the Autonomous
Communities. Autonomous Communities have developed their
numerous supplementary rules. Exporting medicines on which
an export ban was imposed due to shortages and threat of the
danger to public health may result in penalties ranging from EUR
90,000 to EUR 1 million27.
Important measures in Slovakia, primarily aimed at
preventing parallel export of medicines reimbursed in the
country, have come into effect in January 2017. These measures
were also aimed at the removal of accusations for which the
European Commission brought proceedings against the Slovak
Republic (the first banning of re-exporting medicines started in
2012). The new rules ensure that distributors are no longer able
to export drugs covered by public health insurance, since such
exports are only permitted with written authorization/power
26King of Spain. Royal Decree 782/2013 on the Distribution of Medicines for
Human Use (Article 3.3). Spain, 2013.
27Law 29/2006 of July 26. Article 101, c, 22 and Article 102. 1. Spain; 2006.
of attorney of the MAH. Both distributors and producers are
obliged to supply medicines only to local pharmacies. When
attempting to export medicines, distributors must give notice
at least 7 days beforehand. Local pharmacies are also currently
prohibited from re-selling drugs to any distributors except
authorized wholesalers, since in the past the drugs purchased by
distributors from pharmacies were often subsequently exported
(Slovak Parliament, 2011; Pfeffer and Mozolová, 2018). These
recent measures taken in Slovakia have effectively fulfilled
their main objective of preventing the re-export of medicines.
On the other hand, generic pharmaceutical companies started
withdrawing hundreds of generic medicines due to their fear
of huge fines. As mentioned above, all drugs from the national
reimbursement list have to be available within a very short time
from order. In addition, sanctions in the case of breaching the
new law include fines of between EUR 5,000 and EUR 1 million,
as well as the possibility of distributors or pharmacies losing their
operating licenses.
DISCUSSION
Drug shortages emerged as a universal problem in all the
countries studied, regardless of their geographical location, level
of economic development, or type of health care system. Despite
being such a common issue, they are rarely defined in a
precise way within the studied countries’ legislations. Muchmore
frequently, they were defined indirectly or not defined at all. This
finding is consistent with the previous study, according to which
26 very different definitions for drug shortages were identified
globally in 2015 across a wide array of sources, including:
national laws, governmental and professional organizations, and
scientific papers (De Weerdt et al., 2015a), as well as other recent
studies (De Weerdt et al., 2017b). At EU level, the concept of
drug shortages on which the EMA focuses its interest has been
expressed through the description of shortages qualifying for
inclusion into the EMA’s medicine shortages catalog (cit.: “. . .
medicine shortages that affect or are likely to affect more than
one European Union (EU) Member State, where the European
Medicines Agency has assessed the shortage and provided
recommendations to patients and healthcare professionals across
the EU”) (European Medicines Agency, 2017).
The definitions of drug shortages tend to be remarkably
differentiated, depending on whether they pertain to supply
problems or actual drug shortages, permanent or temporal
discontinuations, typology of affected disease classes, and time
frame. Generally, drug shortages can be expressed in four
different ways, according to their focus on either the demand
or supply side, and the way they impact either drug delivery or
availability to patients (De Weerdt et al., 2015a). Besides, the
notion of drug shortages depends very much on stakeholder’s
position within the medicines supply chain: e.g., a manufacturer,
wholesaler, hospital or community pharmacist have varying
perspectives on what constitutes a shortage (Kavanagh, 2017).
Lack of any definition adopted within a national health care
system, as well as diversity of definitions in the same system, or
incomparability and inconsistency of definitions across systems
or countries, can negatively affect reporting, communication,
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and comparative analyses of the problem of drug shortages,
including shortages’ scale and effects. Trying to impose any single
“ideal” definition of drug shortages, officially and internationally
replacing the already existing expressions or descriptions for
the studied phenomenon, is almost impossible and unnecessary.
However, a set of very precisely worded definitions of major
problems should be established, comprehensively defining what
we understand to be drug shortages. This set of definitions
should subsequently be proposed to the international community
of pharmaceutical policy researchers and professionals, then
discussed, mutually agreed, and recommended for wide usage—
at least for the purposes of reporting these drug shortages,
occurring locally or nationally, the reports of which are made
publicly available. In this way, international cooperation on
solving or mitigating the problem of drug shortages would be
facilitated and strengthened.
The need for developing the commonly agreed terminology
(Bogaert et al., 2015) and obtaining a uniform definition for
a drug shortage (De Weerdt et al., 2015a) were reported in
the previous studies as well. Just recently, two draft definitions
of drug shortages were prepared under the auspices of the
WHO (Heiskanen et al., 2017). According to the WHO, on the
supply side: “A “shortage” occurs when the supply of medicines,
health products and vaccines identified as essential by the health
system is considered to be insufficient to meet public health and
patient needs. However, this definition refers only to products
that have already been approved and marketed, in order to
avoid conflicts with research and development agendas.” (World
Health Organization, 2016). On the demand side: “A “shortage”
will occur when demand exceeds supply at any point in the
supply chain and may ultimately create a “stockout” at the point
of appropriate service delivery to the patient if the cause of
the shortage cannot be resolved in a timely manner relative to
the clinical needs of the patient” (World Health Organization,
2016). Hopefully, the efforts of the WHO, pharmaceutical
policy researchers and professionals, and the EMA will finally
result in establishing a set of definitions of drug shortages,
which would be suitable for adoption at the EU level and
globally.
The occurrence of drug shortages in recent years was
rather constant and their dynamics tended to increase—both
features being quite differentiated among the studied countries.
However, due to the existing limitations and variabilities of the
reporting systems, more advanced comparisons and conclusions
are difficult. These could be facilitated not only by using
the commonly agreed definition of the studied problem and
nomenclature for its description, but also having a standardized
methodology of reporting drug shortages. It is plausible that
information on drug shortages is being made publicly available
in many of the studied countries. However, as expected, we found
that these databases are published in local languages only, which
does not help in performing systematic, periodically repeated in-
depth analyses. Having at least a basic, explanatory description
of the structure of each publicly available database on drug
shortages—translated into the widely-used English language—
would facilitate further research. While researching the problem
of drug shortages, it is also important to take into consideration
a baseline level of analysis and the historical circumstances
influencing the development of a given health care system. At
the EU level, involvement of the EMA could have a crucial role,
while the WHO could facilitate efforts at the global level. The
development of initiatives and networks of professionals and
academics, like COST Action CA 15105 “European Medicines
Shortages Research Network—addressing supply problems to
patients (Medicines Shortages),” encouraging systematic sharing
of information and research, seems to be promising and points
the way forward28.
Providing public access or removing obstacles in accessing
drug shortages databases for interested stakeholders, seem to be
the critically important factors which facilitate research on drug
shortages. On the other hand, the dispersion of organizations
responsible for gathering information on drug shortages in
the same country (e.g., Switzerland) can possibly lead to a
multiplication of efforts or confusion in interpreting the results
of analyses—especially when the methodologies of gathering
information are differentiated among such organizations. This
provides an additional rationale not only for developing agreed
and commonly understood sets of definitions, but also for
methodologies for reporting and analyzing drug shortages
within countries. The obligations of the pharmaceutical industry
to notify certain information hubs in cases leading to drug
shortages, existing in the majority of the studied countries,
are crucial with respect to maintaining efficient information
systems.
The role of civil society appears to be important in coping
with the problem of drug shortages. Generally, the multitude
and diversity of organizational frameworks and bottom-up
initiatives, independently developed in the studied countries,
seem to be one of the most inspiring and optimistic findings. We
identified innovative solutions, developed both by governmental
and provincial institutions, as well as grass-roots initiatives
originating at professional organizations or health care providers.
Interestingly, comparison of ingenuity of initiatives developed
in the EU vs. non-EU countries does not seem to reveal major
differences. It has recently been argued that there may be
a potential link between drug shortages and increasing drug
prices, especially in the USA, where health care organizations
are experiencing unexpected price increases for generic or
older products (Fox and Tyler, 2017). For instance, more
than 300 generics in the US experienced price rises of 100%
or more between 2010 and 2015 (Office UGA, 2016). The
factors that can increase the risk of drug shortages are the
same factors that can also augment the risk of raising drug
prices. On the other hand, the same strategies can be used to
manage drug shortages and minimize the impact of unexpected
price increases. Based on this, the clinician checklist was
proposed that includes four steps: (a) assessment of clinical
use; (b) check of purchasing and inventory practices; (c)
evaluation of operational opportunities; and (d) communication
about the issues (Fox and Tyler, 2017). In Canada, the
28COST Action CA 15105. COST Action CA 15105. European Medicines Shortages
Research Network - addressing supply problems to patients (Medicines Shortages).
Available online at: http://www.cost.eu/COST_Actions/ca/CA15105
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best practices guidelines for the prevention, notification, and
management of drug shortages have also been developed
by the pharmaceutical generic industry association. These
guidelines are focused on ways of notification of stakeholders,
communication strategies and management of shortages29.
Regardless of the health care system’s sector, there are a few
common core values that are necessary when handling drug
shortages. These include: establishing effective communication
channels, creating ongoing collaborative relationships among
all the stakeholders (including manufacturers and professional
organizations) and also internally (within an organization),
as well as having keen foresight and acting proactively, as
opposed to just reactively, to a given situation (Dill and Ahn,
2014).
The public service obligation imposed on suppliers of
medicines can potentially play an important role in securing
appropriate access to drugs and preventing their shortages.
However, we found that PSOs are often limited to reimbursed
medicines only, and difficult to execute in practice in the
studied countries. The approach to and interpretation of
a PSO was found to be differentiated, both among the
EU and non-EU/EFTA countries. The standpoint of the
European Association of Pharmaceutical Full-line Wholesalers
(Groupement International de la Répartition Pharmaceutique—
GIRP) is that provisions of the PSO for persons active in the
distribution of medicines should be compulsory in all Member
States of the EU30. PSOs imposed on full-line wholesalers are
aimed to secure the patients with several benefits. They can
receive their medicines in a timely and safe manner from
reliable and certified sources, which offer an adequate range of
permanently guaranteed products to them. Besides, due to the
PSO, the medicines which patients receive meet the requirements
of a specific geographical area, and are delivered according to
the supplies requested within a short timeframe. Consequently,
according to the GIRP, the European framework providing for
PSOs for pharmaceutical full-line wholesalers would enhance
and strengthen the guarantee to patients in obtaining their
medicines30. The European Association of Pharmaceutical
Industries and Associations admits that strict adherence to
regulatory obligations is essential to the integrity and reliability
of the overall supply chain, while PSO should be interpreted
and enforced in a proactive manner which prioritizes patient
29Canadian Generic Pharmaceutical Association. Canadian Generic
Pharmaceutical Association (CGPA) Best Practices Guidelines for the Prevention,
Notification and Management of Drug Shortages. Available online at: https://
www.google.pl/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=
8&ved=0ahUKEwjw76ew9oHWAhXLPhQKHS4MD48QFggmMAA&url=http
%3A%2F%2Fcanadiangenerics.ca%2Fwp-content%2Fuploads%2F2016%2F09
%2FBestPracticesGuidelines2013.pdf&usg=AFQjCNHfkDUPTKfKbHV3Is
30GIRP European Association of Pharmaceutical Full-line Wholesalers.
European Association of Pharmaceutical Full-line Wholesalers (GIRP)
response to the European Commission Consultation regarding Community
action on Health Services Introduction. Available online at: https://
www.google.pl/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&ved=
0ahUKEwjCxufIn4LWAhVBWhQKHTM6CAAQFghUMAY&url=
http%3A%2F%2Fec.europa.eu%2Fhealth%2Farchive%2Fph_overview
%2Fco_operation%2Fmobility%2Fdocs%2Fhealth_services_co76.pdf&usg=
AFQjCNH2dxEuBukj_AoN
safety (European Association of Pharmaceutical Industries
Associations, 2014). PSOmust be warranted on grounds of public
health protection, and proportionate in relation to the objective
of such protection20.
The possibility to prescribe unlicensedmedicines in the case of
non-availability of other medicines, is an important public health
safety measure, especially in smaller countries where the size of
the pharmaceutical market and the number of potential users
are not particularly attractive to the pharmaceutical companies.
Generally, in smaller countries we found several interesting
initiatives to cope with the problem of drug shortages, such as
multi-language labeling or simplified labeling in some limited
cases.
Parallel trade or arbitrage on a pharmaceutical market is a very
complicated issue. In the EU, it is founded on the cardinal rule of
free trade of goods, while on the other hand the Member States
are responsible for their independent, national, or even local
pharmaceutical policies (including pricing and reimbursement).
Being supported by these two pillars, parallel trade in the EU
has very differentiated implications. For example, its impact on
patients’ expenditures on medicines as it is very much dependent
on the rules of copayment (Kanavos et al., 2004, 2006; Glynn,
2006). Parallel trade impacts the pharmaceutical trade as well as
health care systems, and patients in numerous and sometimes
unexpected ways; nevertheless, it seems that the EU is simply
destined to function with parallel trade of medicines.
As it was revealed already in 2004, in the report on the
economic impact of pharmaceutical parallel trade in EUMember
States, the price spread between an exporting and importing
country was a key factor in determining the potential for
parallel trade, with the market size of the importing country
determining its extent (Kanavos et al., 2004). The direct
financial effects were assessed in six countries, and 19 products
were analyzed in that report. Patients were found not to
be benefitting directly from parallel trade, while the financial
benefits accrued to health insurance organizations or pharmacists
were, at best, modest. Significant benefits were identified among
parallel importers, while manufacturers (particularly of products
under patent) incurred a significant loss of business in the
destination countries. The hypotheses of price convergence
across (importing and exporting) countries, as well as price
competition and a downward price spiral within importing
countries, were rejected. Taking into account that some exporting
countries may experience product shortages, it was concluded
in that report that the static welfare effect of parallel trade was
at best neutral (Kanavos et al., 2004). Our findings indicate
that parallel trade is perceived as a major factor contributing
to drug shortages and that an increasing number of states
are implementing legal solutions aimed at controlling parallel
export from their national territories. We found increasing
efforts to curb parallel export in cases when it hampers the
secure provision of medicines to citizens and more generally—
public health. It should be stressed that the real impact of
drug shortages (considering their diversity and assortment) on
public health is still not known precisely in many countries.
While the significance of life-threatening shortages of certain
medicinal products is indisputable, in many cases the share of
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life-threatening shortages among all the shortages often remains
unknown or unquantified.
There appears to be an insufficient role and relatively poor
engagement of the EU bodies in coping with the problem of
drug shortages. The need for a greater involvement of the EU
institutions has been already expressed in Ireland. In its 2016–
2020 strategic plan, the Irish HPRA suggested that more effective
solutions will be possible through EU co-operation on issues such
as medicines shortages (Health Products Regulatory Authority,
2016). The role and engagement of relevant EU bodies seems to
be especially important nowadays in light of the differentiated,
and just recovering from the lower levels, image of the EU
among citizens of the Member States (40% of total positive
answers in 2017 vs. 52% in 2007, according to the Eurobarometer
periodic survey), along with the only just recovering trust
toward EU institutions (42% tending to trust in 2017 vs.
57% in 2007) (European Commission Standard Eurobarometer,
2017). The stronger involvement of EU institutions in coping
with the problem of drug shortages could be an appreciable
opportunity to stand by the citizens of virtually all Member
States, since the problem of drug shortages is vital to all citizens,
patients, and their families across the whole of the European
Union.
It should be noted that this study is not without limitations.
The large number of countries and the broad scope of the
issues investigated prohibited the authors from conducting an
in-depth analysis of each aspect of drug shortages. The choice
of survey respondents mainly from national health authorities
and the policy area, and not taking the perspective of other
stakeholders, such as manufacturers, wholesalers, or pharmacists
with knowledge of the problems and potential interventions,
could give a one-sided perspective and potentially bias the
results. Furthermore, utilizing the personal knowledge of survey
participants, even expanded by using the published sources as
well, could be a further potential limitation of the study. However,
we typically took the health authority perspective as they are
the ultimate payers. The methodology applied in this study and
character of the gathered material also did not allow for detailed
quantitative assessment and comparative analysis of the extent
of drug shortages, the assortment of products with shortages
and the changes in shortages of certain medicines over time.
Consequently, appropriateness and effectiveness of potential
interventions, which could be different for unpredictable and
predictable shortages, could not be fully assessed based on
the gathered material. More detailed characteristics of drug
shortages, analyses of information systems and their role in
coping with shortages, detailed descriptions of initiatives, and
organizational frameworks preventing shortages, as well as
analyzing how interventions into trade rules, including also
the approach to parallel trade or arbitrage, should be further
studied and internationally compared and evaluated to provide
potential ways forward. However, the authors believe that this
study provides a very comprehensive overall picture of the drug
shortages landscape in a broad range of countries and lays
out directions for possible future research. Considering the still
limited evidence on drug shortages, the authors have focused
on including various European and Western Asian countries in
order to provide a broad overview in a single study. This has
inevitably raised the issue of comparability of national or local
experiences. However, the authors believe that their inclusive
approach has resulted in more advantages than constraints in the
interpretation and drawing up of lessons for the future.
CONCLUSIONS
Very different definitions of drug shortages exist in a small
number of countries, while in the majority, no definition was
adopted at all. There is an urgent need to develop an agreed
set of definitions of drug shortages, as well as methodologies
for drug shortages’ evaluation and monitoring. They should be
proposed, discussed among pharmaceutical policy researchers
and professionals, and agreed and adopted for use on an
international scale. There is a role for the WHO and the EMA
to further engage and take a lead.
The characteristics of drug shortages, including their duration,
frequency, dynamics and assortment of products are variable
and sometimes difficult to assess. Although drug shortages have
been very often, or always, present in the majority of studied
countries, they are now universally perceived as a public health
problem. There usually exist information hubs in the studied
countries gathering evidence on drug shortages. Sometimes the
content of the databases is limited to reimbursed products only,
or not fully disclosed to the public. Providing public access to
information on drug shortages, to the maximum extent possible,
is a prerequisite for performing more advanced studies on the
problem and identifying its solutions.
An optimistic finding of this study was the identification of
numerous bottom-up initiatives and organizational frameworks
aimed at preventing or mitigating drug shortages. The efforts of
governments or state health authorities are often supplemented
or excelled by independent actions originating at pharmacies,
professional organizations or associations, as well as lower-
level local health authorities. However, the need for bottom up
approaches could also be a symptom of the national regulatory
bodies not adequately addressing the issue. The experiences and
lessons drawn from these initiatives should be carefully evaluated,
monitored, and presented to the wider international audience for
potential development beyond the local country. This paper is a
start in this process.
The various forms of influencing trade rules, as the strategies
for coping with the problem of drug shortages, are being
implemented in the studied countries. Imposing PSO on
pharmaceutical manufacturers, wholesalers, or pharmacies is
rather difficult, especially in smaller countries. Providing the
formal possibility to prescribe (and trade) unlicensed medicines,
when necessary, is a widespread measure to prevent serious
crises in drug supply chains and health care systems. Influencing
rules of parallel trade or arbitrage, through imposing bans on
exporting medicines in the case of threat to public health evoked
by drug shortages, is increasingly gaining in popularity, and will
continue.
The authors’ intention is that this paper provides
a platform to tackle the increasingly important public
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health issue of drug shortages, and will be taken forward
by them.
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